Literature DB >> 34315566

Artificial Intelligence-Enabled Electrocardiography to Screen Patients with Dilated Cardiomyopathy.

Sanskriti Shrivastava1, Michal Cohen-Shelly1, Zachi I Attia1, Andrew N Rosenbaum1, Liwei Wang2, John R Giudicessi1, Margaret Redfield1, Kent Bailey2, Francisco Lopez-Jimenez1, Grace Lin1, Suraj Kapa1, Paul A Friedman1, Naveen L Pereira3.   

Abstract

Undiagnosed dilated cardiomyopathy (DC) can be asymptomatic or present as sudden cardiac death, therefore pre-emptively identifying and treating patients may be beneficial. Screening for DC with echocardiography is expensive and labor intensive and standard electrocardiography (ECG) is insensitive and non-specific. The performance and applicability of artificial intelligence-enabled electrocardiography (AI-ECG) for detection of DC is unknown. Diagnostic performance of an AI algorithm in determining reduced left ventricular ejection fraction (LVEF) was evaluated in a cohort that comprised of DC and normal LVEF control patients. DC patients and controls with 12-lead ECGs and a reference LVEF measured by echocardiography performed within 30 and 180 days of the ECG respectively were enrolled. The model was tested for its sensitivity, specificity, negative predictive (NPV) and positive predictive values (PPV) based on the prevalence of DC at 1% and 5%. The cohort consisted of 421 DC cases (60% males, 57±15 years, LVEF 28±11%) and 16,025 controls (49% males, age 69 ±16 years, LVEF 62±5%). For detection of LVEF≤45%, the area under the curve (AUC) was 0.955 with a sensitivity of 98.8% and specificity 44.8%. The NPV and PPV were 100% and 1.8% at a DC prevalence of 1% and 99.9% and 8.6% at a prevalence of 5%, respectively. In conclusion AI-ECG demonstrated high sensitivity and negative predictive value for detection of DC and could be used as a simple and cost-effective screening tool with implications for screening first degree relatives of DC patients.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34315566     DOI: 10.1016/j.amjcard.2021.06.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

Review 1.  Artificial Intelligence Applied to Cardiomyopathies: Is It Time for Clinical Application?

Authors:  Kyung-Hee Kim; Joon-Myung Kwon; Tara Pereira; Zachi I Attia; Naveen L Pereira
Journal:  Curr Cardiol Rep       Date:  2022-09-01       Impact factor: 3.955

Review 2.  Clinical significance, challenges and limitations in using artificial intelligence for electrocardiography-based diagnosis.

Authors:  Cheuk To Chung; Sharen Lee; Emma King; Tong Liu; Antonis A Armoundas; George Bazoukis; Gary Tse
Journal:  Int J Arrhythmia       Date:  2022-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.